Brief: Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability With CDK4/6 Inhibitors Ribociclib And Palbociclib In Phase 1B/2 Studies

Olema Pharmaceuticals

05/12/2023 17:37

Dec 5 (Reuters) - Olema Pharmaceuticals Inc  OLMA.O :
    * OLEMA ONCOLOGY ANNOUNCES PALAZESTRANT DEMONSTRATES
ATTRACTIVE
COMBINABILITY WITH CDK4/6 INHIBITORS RIBOCICLIB AND PALBOCICLIB
IN PHASE 1B/2 STUDIES
    * OLEMA PHARMACEUTICALS INC -  PALAZESTRANT (OP-1250) IN
COMBINATION WITH CDK 4/6 INHIBITORS DEMONSTRATED NO SIGNIFICANT
DRUG-DRUG INTERACTION
    * OLEMA PHARMACEUTICALS:  PALAZESTRANT (OP-1250) IN
COMBINATION
WITH CDK 4/6 INHIBITORS DEMONSTRATED NO DOSE-LIMITING TOXICITIES
    * OLEMA PHARMA - OPERA-01 TRIALS-IN-PROGRESS POSTER OUTLINES
PHASE
3 TRIAL DESIGN;CLINICAL SITES ACTIVATED,ENROLLING WITH 1ST
PATIENT DOSED IN NOV
    * OLEMA: PALAZESTRANT WITH CDK 4/6 INHIBITORS SHOWED
TOLERABILITY
PROFILE CONSISTENT WITH FDA-APPROVED CDK 4/6 INHIBITORS LABELS
PLUS ENDOCRINE THERAPY

Source text for Eikon:  ID:nGNX16C1FM 
Further company coverage:  OLMA.O 

 ((Reuters.Briefs@thomsonreuters.com;))